Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patients

Introduction: In 2017 the drug chenodeoxycholic acid (CDCA) became unavailable to Dutch patients with the rare inborn error of metabolism cerebrotendinous xanthomatosis (CTX). This was a direct result of a steep price increase after CDCA was authorized in the EU as an orphan drug. As a result, Dutch...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwhuis, Natalja, Jacobs, Bart A. W., Kemper, E. Marleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616945/
https://www.ncbi.nlm.nih.gov/pubmed/37915417
http://dx.doi.org/10.3389/fphar.2023.1264997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616945/
https://www.ncbi.nlm.nih.gov/pubmed/37915417
http://dx.doi.org/10.3389/fphar.2023.1264997

Ejemplares similares